91 Days
Source:
المشهد
Source: المشهد
91 Daysالمشهد
Source: المشهد
91 DaysReady to play
Ready to play
The U.S. Food and Drug Administration (FDA) has approved the first influenza vaccine based on messenger RNA (mRNA) technology, representing a new vaccination option for individuals aged over 50. The vaccine received full approval for the age group between 50 and 64 years, while emergency approval was granted for those over 65, with additional studies underway to assess its effectiveness in older adults. Data show that the vaccine is approximately 27% more effective in preventing influenza compared to traditional vaccines, and it is expected to be available in retail stores in the coming weeks. This vaccine aims to enhance the speed of influenza vaccine development and better keep up with evolving virus strains.
Notice: This Is an AI-Generated Summary
Comments (0)